Background Direct oral anticoagulants (DOAC s) have been proposed as a more convenient
alternative to vitamin K antagonists (VKA s), which are commonly associated with poor …

Background—The safety and effectiveness of non–vitamin K antagonist (VKA) oral
anticoagulants, dabigatran or rivaroxaban, were compared with VKA in anticoagulant-naive …

This study examined characteristics and treatment persistence among patients prescribed
oral anticoagulants (OACs) for stroke prevention in non-valvular atrial fibrillation (NVAF). We …

Objective: To compare real-world persistence and discontinuation among non-valvular atrial
fibrillation (NVAF) patients on rivaroxaban and dabigatran in the US. Methods: A large …

Objective To determine discontinuation rates, patterns of use and predictors of
discontinuation of non-vitamin K antagonist oral anticoagulants (NOACs) among patients …

Objective Dabigatran and rivaroxaban are novel oral anticoagulants (NOACs) approved for
stroke prevention in atrial fibrillation (AF). Although NOACs are more convenient than …

Background Persistence to treatment affects clinical outcomes in patients with chronic
disease such as atrial fibrillation (AF). Methods This prospective cohort study included …

Objective Unlike several other national health agencies, French health authorities
recommended that the newer direct oral anticoagulant (DOAC) agents only be prescribed as …

Background: The new generation, non-vitamin K antagonist oral anticoagulants are used in
an increasing frequency, partially replacing the vitamin K antagonists in several fields of …

Aim To assess persistence and adherence to rivaroxaban, dabigatran, and vitamin K
antagonist (VKA) treatment in primary care patients with non-valvular atrial fibrillation (AF) …